JP7650800B2 - アデノ随伴ウイルス（ａａｖ）産生細胞株および関連方法 - Google Patents

アデノ随伴ウイルス（ａａｖ）産生細胞株および関連方法 Download PDF

Info

Publication number
JP7650800B2
JP7650800B2 JP2021535829A JP2021535829A JP7650800B2 JP 7650800 B2 JP7650800 B2 JP 7650800B2 JP 2021535829 A JP2021535829 A JP 2021535829A JP 2021535829 A JP2021535829 A JP 2021535829A JP 7650800 B2 JP7650800 B2 JP 7650800B2
Authority
JP
Japan
Prior art keywords
promoter
gene
mammalian cell
aav
control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021535829A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020132059A5 (https=
JP2022516004A (ja
JP2022516004A5 (https=
Inventor
ビンナン グ，
ケイトリン エム． グエンザー，
アナンディタ セス，
Original Assignee
ロンザ ウォーカーズヴィル，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ロンザ ウォーカーズヴィル，インコーポレーテッド filed Critical ロンザ ウォーカーズヴィル，インコーポレーテッド
Publication of JP2022516004A publication Critical patent/JP2022516004A/ja
Publication of JPWO2020132059A5 publication Critical patent/JPWO2020132059A5/ja
Publication of JP2022516004A5 publication Critical patent/JP2022516004A5/ja
Priority to JP2025039219A priority Critical patent/JP2025102801A/ja
Application granted granted Critical
Publication of JP7650800B2 publication Critical patent/JP7650800B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/40—Vector systems having a special element relevant for transcription being an insulator
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021535829A 2018-12-21 2019-12-18 アデノ随伴ウイルス（ａａｖ）産生細胞株および関連方法 Active JP7650800B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025039219A JP2025102801A (ja) 2018-12-21 2025-03-12 アデノ随伴ウイルス（ａａｖ）産生細胞株および関連方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862783589P 2018-12-21 2018-12-21
US62/783,589 2018-12-21
US201962866092P 2019-06-25 2019-06-25
US62/866,092 2019-06-25
PCT/US2019/067156 WO2020132059A1 (en) 2018-12-21 2019-12-18 Adeno-associated virus (aav) producer cell line and related methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025039219A Division JP2025102801A (ja) 2018-12-21 2025-03-12 アデノ随伴ウイルス（ａａｖ）産生細胞株および関連方法

Publications (4)

Publication Number Publication Date
JP2022516004A JP2022516004A (ja) 2022-02-24
JPWO2020132059A5 JPWO2020132059A5 (https=) 2022-12-26
JP2022516004A5 JP2022516004A5 (https=) 2022-12-26
JP7650800B2 true JP7650800B2 (ja) 2025-03-25

Family

ID=71099162

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021535829A Active JP7650800B2 (ja) 2018-12-21 2019-12-18 アデノ随伴ウイルス（ａａｖ）産生細胞株および関連方法
JP2025039219A Pending JP2025102801A (ja) 2018-12-21 2025-03-12 アデノ随伴ウイルス（ａａｖ）産生細胞株および関連方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025039219A Pending JP2025102801A (ja) 2018-12-21 2025-03-12 アデノ随伴ウイルス（ａａｖ）産生細胞株および関連方法

Country Status (8)

Country Link
US (2) US11739347B2 (https=)
EP (1) EP3891290A4 (https=)
JP (2) JP7650800B2 (https=)
KR (1) KR20210108423A (https=)
CN (1) CN113396222A (https=)
IL (1) IL284219A (https=)
SG (1) SG11202106217TA (https=)
WO (1) WO2020132059A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4189077A1 (en) * 2020-07-30 2023-06-07 Shape Therapeutics Inc. Stable cell lines for inducible production of raav virions
EP4229205B1 (en) * 2020-10-15 2025-05-14 F. Hoffmann-La Roche AG Nucleic acid constructs for va rna transcription
CN112501209B (zh) * 2020-12-07 2024-02-13 和元生物技术（上海）股份有限公司 外源基因可控表达的腺相关病毒包装方法
CN116829725A (zh) * 2021-02-12 2023-09-29 富士胶片株式会社 用于产生腺相关病毒的试剂盒及其利用
EP4322975A4 (en) * 2021-04-14 2025-03-26 Capsida, Inc. PLASMIDS AND PROCESSES FOR PRODUCING ADENO-ASSOCIATED VIRUSES
EP4410971A4 (en) * 2021-09-30 2025-06-04 FUJIFILM Corporation METHOD FOR PRODUCING AN ADENO-ASSOCIATED VIRUS, CELLS AND EXPRESSION VECTOR
AU2022373653A1 (en) * 2021-10-18 2024-05-02 Regeneron Pharmaceuticals, Inc. Eukaryotic cells comprising adenovirus-associated virus polynucleotides
EP4473123A4 (en) * 2022-02-01 2026-03-11 Shape Therapeutics Inc STABLE CELL LINES FOR INDUCIBLE VAAR VIRION PRODUCTION
EP4491717A4 (en) 2022-03-08 2025-11-12 Fujifilm Corp PRODUCING CELL, PRODUCTION METHOD FOR PRODUCING PRODUCING CELLS AND PRODUCTION METHOD FOR ADENE-ASSOCIATED VIRUS
CN120092093A (zh) * 2022-08-25 2025-06-03 富士胶片株式会社 靶病毒的制造方法及培养组合物
EP4624584A1 (en) * 2022-12-27 2025-10-01 Synplogen Co., Ltd. Helper gene control
US12410436B2 (en) * 2023-10-31 2025-09-09 Lonza Houston, Inc. Adeno-associated virus (AAV) producer cell lines
WO2025122676A1 (en) * 2023-12-05 2025-06-12 Shape Therapeutics Inc. Systems and methods for raav production using a biphasic culture
WO2025168663A1 (en) 2024-02-09 2025-08-14 F. Hoffmann-La Roche Ag Method for producing recombinant adeno-associated viral particles
WO2025252480A1 (en) 2024-06-07 2025-12-11 F. Hoffmann-La Roche Ag Method for purifying plasmid dna
CN118460545B (zh) * 2024-07-08 2025-02-11 凌意(杭州)生物科技有限公司 一种诱导型表达Rep多肽的表达框
US20260022401A1 (en) 2024-07-22 2026-01-22 Hoffmann-La Roche Inc. Novel AAV rep ORFs and Rep polypeptides
WO2026037757A1 (en) 2024-08-13 2026-02-19 F. Hoffmann-La Roche Ag Modified aav particles
WO2026044087A1 (en) * 2024-08-21 2026-02-26 Shape Therapeutics Inc. Increased cellular stability for aav production

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180327722A1 (en) 2017-04-18 2018-11-15 Glaxosmithkline Intellectual Property Development Limited Methods for Adeno-Associated Viral Vector Production

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622856A (en) 1995-08-03 1997-04-22 Avigen High efficiency helper system for AAV vector production
US6037177A (en) * 1997-08-08 2000-03-14 Cell Genesys, Inc. Method for increasing the efficiency of recombinant AAV production
JP2002153278A (ja) * 2000-11-22 2002-05-28 Hisamitsu Pharmaceut Co Inc ウイルスベクターの製造に用いられる細胞、その製法およびその細胞を用いたウイルスベクターの製造方法
AU2002305778A1 (en) * 2001-05-31 2002-12-09 The Rockefeller University Method for generating replication defective viral vectors that are helper free
AU2002367943A1 (en) * 2001-12-18 2003-12-22 University Of North Carolina At Chapel Hill Improved reagents and methods for producing parvoviruses
EP1844148A2 (en) 2005-01-31 2007-10-17 University of Iowa Research Foundation Nucleic acid silencing of huntington's disease gene
US20130023033A1 (en) * 2010-03-29 2013-01-24 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
JP6661544B2 (ja) 2014-04-24 2020-03-11 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子改変したｔ細胞の自動生成法
JP2018508223A (ja) * 2015-03-16 2018-03-29 ボード・オブ・トラスティーズ、サザン・イリノイ・ユニバーシティ 安定な遺伝子発現のための系
WO2018136566A1 (en) 2017-01-18 2018-07-26 F1 Oncology, Inc. Methods of transducing and expanding immune cells and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180327722A1 (en) 2017-04-18 2018-11-15 Glaxosmithkline Intellectual Property Development Limited Methods for Adeno-Associated Viral Vector Production

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MACHITANI, Mitsuhiro et al.，Journal of Controlled Release，2011年09月25日，Vol. 154, Issue 3，pp. 285-289，DOI: 10.1016/j.jconrel.2011.06.020
TORDO, Julie et al.，Brain，2018年07月，Vol. 141, No. 7，pp. 2014-2031，DOI: 10.1093/brain/awy126
ZHOU, Heshon and BEAUDET, Arthur L.，Virology，2000年09月30日，Vol. 275, Issue 2 ，pp. 348-357，DOI: 10.1006/viro.2000.0515

Also Published As

Publication number Publication date
CN113396222A (zh) 2021-09-14
US11739347B2 (en) 2023-08-29
EP3891290A1 (en) 2021-10-13
KR20210108423A (ko) 2021-09-02
JP2022516004A (ja) 2022-02-24
US20240018545A1 (en) 2024-01-18
IL284219A (en) 2021-08-31
WO2020132059A1 (en) 2020-06-25
EP3891290A4 (en) 2022-11-02
US12529074B2 (en) 2026-01-20
SG11202106217TA (en) 2021-07-29
US20200199627A1 (en) 2020-06-25
JP2025102801A (ja) 2025-07-08

Similar Documents

Publication Publication Date Title
JP7650800B2 (ja) アデノ随伴ウイルス（ａａｖ）産生細胞株および関連方法
US20220259572A1 (en) Adeno-associated virus (aav) production
US20250066744A1 (en) Automated production of viral vectors
US6953690B1 (en) Compositions and methods for helper-free production of recombinant adeno-associated viruses
CA3112883A1 (en) Aav triple-plasmid system
CN110785495A (zh) 腺相关病毒载体的生产方法
WO1999047691A1 (en) Compositions and methods for helper-free production of recombinant adeno-associated viruses
EP4229205B1 (en) Nucleic acid constructs for va rna transcription
US20230018373A1 (en) Automated production of viral vectors
US12410436B2 (en) Adeno-associated virus (AAV) producer cell lines
JP2024501223A (ja) 低レベルのｖａ－ｒｎａを有する産生細胞
AU2024371130A1 (en) Adeno-associated virus (aav) producer cell lines
WO2026003353A1 (en) Genetic constructs for improved aav titers and potency
EP4671265A1 (en) GENETIC CONSTRUCTIONS FOR ENHANCED AAV TITLES AND ASSOCIATED USEFUL POWER
HK40048431A (en) Automated production of viral vectors
IL310949A (en) A method for preparing an adapted adeno-associated virus envelope

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250312

R150 Certificate of patent or registration of utility model

Ref document number: 7650800

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150